Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology.

By F. Malavasi, S. Deaglio, A. Funaro, E. Ferrero, A. Horenstein, E. Ortolan, T. Vaisitti, Semra Aydın. Physiological Reviews, 2008

854 citations recorded by the source corpus.

Subfields: Oncology, Physiology

View Paper: https://www.semanticscholar.org/paper/9672964692b3150f2986def6d118a268178fd463

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Johan Auwerx
2. C. Cantó
3. S. Imai

In Physiology

1. Johan Auwerx
2. Keir J. Menzies
3. C. Cantó
4. S. Imai
5. Jun Yoshino
6. E. Verdin
7. Joseph A. Baur
8. D. Sinclair

Citations in the corpus

• Novel Markers to Delineate Murine M1 and M2 Macrophages (2015, background): “CD38 is often referred to as an activation marker expressed on lymphocytes, neutrophils and NK cells upon inflammatory conditions [59].”
• NAD+ metabolism and the control of energy homeostasis - a balancing act between mitochondria and the nucleus (2015, background): “NAD+-Consuming Enzymes (III): Cyclic ADP-Ribose Synthases Cyclic ADP-ribose (cADPR), a secondary messenger implicated in Ca2+ signaling, cell cycle control and insulin signaling (Malavasi et al., 2008), is produced from NAD+ by cADPR synthases.”
• CD38 dictates age-related NAD decline and mitochondrial dysfunction through a SIRT3-dependent mechanism (2016, neutral): “CD38 was originally identified as a cell-surface enzyme that plays a key role in several physiological processes such as immune response, inflammation, cancer, and metabolic disease (Barbosa et al., 2007; Frasca et al., 2006; Guedes et al., 2008; Malavasi et al., 2008).”
• SOX17 is a Critical Specifier of Human Primordial Germ Cell Fate (2014, background): “CD38: ACoreMarker of HumanGerm-Cell-Related Cells and Initiation of the Epigenetic Program CD38, an established cell-surface glycoprotein on leukocytes, is a prognostic marker of leukemia (Malavasi et al., 2008).”
• Therapeutic potential of NAD-boosting molecules: the in vivo evidence (2018, neutral): “To a lesser extent, both enzymes also act as ADP-ribosyl cyclases that catalyze the hydrolysis of NAD+ to generate NAM and cADPR, a Ca2+-mobilizing second messenger active in many cell types (Berthelier et al., 1998; Kirchberger and Guse, 2013; Malavasi et al., 2008).”